Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for MIRA Pharmaceuticals, Inc. (MIRA : NSDQ)
 
 • Company Description   
MIRA Pharmaceuticals Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. MIRA Pharmaceuticals Inc. is based in Baltimore, Maryland.

Number of Employees: 5

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.20 Daily Weekly Monthly
20 Day Moving Average: 2,291,726 shares
Shares Outstanding: 16.92 (millions)
Market Capitalization: $20.30 (millions)
Beta: 1.72
52 Week High: $5.01
52 Week Low: $0.58
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -3.23% -6.85%
12 Week 27.81% 7.50%
Year To Date 5.26% -1.42%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1200 BRICKELL AVENUE SUITE 1950 #1183
-
MIAMI,FL 33131
USA
ph: 786-432-9792
fax: -
info@mirapharma.com https://mirapharmaceuticals.com
 
 • General Corporate Information   
Officers
Erez Aminov - Chief Executive Officer and Chairman
Michelle Yanez - Chief Financial Officer; Secretary and Treasurer
Matthew Whalen - Director
Matthew Del Giudice - Director
Denil Shekhat - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 60458C104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 16.92
Most Recent Split Date: (:1)
Beta: 1.72
Market Capitalization: $20.30 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.11 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.44 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 15.59
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 8.33%
vs. Previous Quarter: 26.67%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -341.08
12/31/24 - -281.72
ROA
06/30/25 - -
03/31/25 - -272.93
12/31/24 - -224.13
Current Ratio
06/30/25 - -
03/31/25 - 12.86
12/31/24 - 3.99
Quick Ratio
06/30/25 - -
03/31/25 - 12.86
12/31/24 - 3.99
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - 0.08
12/31/24 - 0.13
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©